fingolimod hydrochloride has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huwiler, A; Pfeilschifter, J; Schwalm, S | 1 |
| Goto, R; Ichimaru, N; Kangawa, K; Kawano, Y; Moriyama, T; Nakahama, H; Okuyama, A; Sada, M; Shi, Y; Takahara, S; Yazawa, K; Yoshihara, F | 1 |
1 review(s) available for fingolimod hydrochloride and Bright Disease
| Article | Year |
|---|---|
Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Glomerulonephritis; Humans; Inflammation; Kidney Failure, Chronic; Lysophospholipids; Molecular Targeted Therapy; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2014 |
1 other study(ies) available for fingolimod hydrochloride and Bright Disease
| Article | Year |
|---|---|
A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis.
Topics: Adrenomedullin; Animals; Autoimmune Diseases; Blood Chemical Analysis; Fingolimod Hydrochloride; Glomerulonephritis; Humans; Immunosuppressive Agents; Kidney; Male; Mercuric Chloride; Peptides; Propylene Glycols; Proteinuria; Radioimmunoassay; Random Allocation; Rats; Sphingosine; Statistics as Topic; Urine | 2005 |